Photo of Jamal Rahaman

Jamal Rahaman

  • ASSOCIATE CLINICAL PROFESSOR Obstetrics, Gynecology and Reproductive Science
Print ProfilePrint Profile

Clinical Focus


  • MD, University of the West Indies

  • Residency, Obs/ Gyn
    Mount Hope Women's Hospital

  • Residency, Obs/ Gyn
    Lincoln Medical & Mental Health Ct.

  • Residency, Obs/ Gyn
    Mount Sinai Hospital

  • Fellowship, Cardio & Vascular
    Texas Heart Institute

  • Fellowship, Gynecology Oncology
    Mount Sinai Hospital


    Jamal Rahaman, MD, DGO, FACS, FACOG

    Dr. Rahaman previously served as the Fellowship Director in the Division of Gynecologic Oncology and the Director of the Gynecologic Oncology Chemotherapy Service at the Mount Sinai Medical Center. He has also previously served as the Director of Gynecologic Oncology at the Mount Sinai and Elmhurst Hospitals.

    Dr. Rahaman received his medical training at The University of the West Indies and did his first Residency in Obstetrics and Gynecology at The Mount Hope Women's Hospital, in a Royal College of Obstetricians & Gynecologists Program. He also completed the full Residency in Obstetrics and Gynecology at The Mount Sinai Medical Center. In addition to the Fellowship training in Gynecologic Oncology at Mount Sinai, he also completed a two year Fellowship in Cardiac and Vascular surgery with Dr. Denton Cooley at the Texas Heart Institute. After serving as Chairman of The Department of Obstetrics & Gynecology at the Williamson ARH Hospital in Kentucky, he was recruited to return to the Faculty at Mount Sinai in the Division of Gynecologic Oncology.

    Dr. Rahaman's academic responsibility focuses on the comprehensive training of subspecialty fellows in Gynecologic Oncology in addition to teaching resident physicians and medical students. He is widely recognized for his special expertise in complicated and challenging pelvic surgery especially laparoscopic and minimally invasive surgery. He is one of a very few surgeons credentialed to teach and perform da Vinci Robotic surgery for Gynecologic cancers. He is the Principal and co-investigator on several National & International Clinical trials for gynecologic cancers including GOG chemotherapy trials and HPV vaccination trials. Dr. Rahaman is also engaged in basic science and translational research to identify potential predictors of malignant transformation to ovarian cancers as well as investigating novel targets and pathways for emerging cancer therapeutic agents. He has authored numerous publications in International journals and written several book chapters in Gynecologic Oncology and has been the recipient of many teaching and peer recognition awards. His clinical practice encompasses the full spectrum of care for gynecologic cancers including surgery, chemotherapy and biologic therapy. He is also a certified colposcopist for Cervical Dysplasia clinical trials and provides complete treatment for pre-invasive lower genital tract disease including laser therapy.

    Related Link:
    Mount Sinai Gynecologic Oncology Fellowship Program


  • 2008 -
    Marquis-Who's Who in America

  • 2008 -
    Biltmore Who's Who

  • 2008 -
    Best Doctors in New York
    New York Magazine

  • 2002 -
    Top Minimal Invasive Surgeons
    New York Magazine

  • 2002 - 2008
    Top Doctors in New York Metro Area
    Castle Conolly Medical

  • 2002 -
    1st Place
    ACOG Annual Meeting Film Festival

  • 2001 -
    CREOG/ACOG National Faculty Teaching Award for Residency Education

  • 1990 -
    Resident of the Year Award
    Lincoln Medical Center

  • 1984 -
    Leonard de Cordova Medal in Physiology

  • 1984 -
    Noel Haye Prize

  • 1984 -
    Class Prize in Internal Medicine

  • 1979 -
    Trinidad and Tobago National Scholarship

  • 1979 -
    University of the West Indies Open Scholarship


Active Clinical Trials

A Phase III Trial of Carboplatin and Paclitaxel plus placebo versus Carboplatin and Paclitaxel plus concurrent Bevacizumab (NSC # 704865, IND #7921) followed by placebo, versus Carboplatin and Paclitaxel plus concurrent and extended Bevacizumab, in women who are newly diagnosed, previously untreated, Stage III or IV, epithelial overian or primary peritoneal cancer NCI-supplied agent(s): Bevacizumab/Placebo (NSC #704865, IND #7921)

GOG0213 A Phase III randomized controlled clinical trial of Carboplatin and Paclitazel alone or in combination with Bevacizumab (NSC #704865, IND #7921) followed by Bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritone primary and fallopian tube cancer.  NCI-supplied agents: Bevacizumab (NSC #704865, IND #7921)

A randomized phase III trial of maintenance chemotherapy comparing 12, monthly cycles of single agent Paclitaxel or CT-2103 (IND #70177), versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer achieve a complete clinical response to primary platinum/taxane chemotherapy

A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer

A Molecular Staging Study of Endometrial Carcinoma

GOG0233 / ACRIN 6671
Utility of preoperative FDG-PET/CT and Ferumoxtran-10 MRI scanning prior to primary chemoradiation therapy to detect retroperitoneal lymph node metastasis in patients with locoregionally advanced (IB2, IIA ≥4 CM, IIB-IVA) carcinoma of the cervix

A Phase II Randomized Study of the Effect of Zoledronic Acid versus Observation on Bone Mineral Density of the Lumbar Spine in Women who Elect to Undergo Risk-Reducing Surgery that Results in Removal of Both Ovaries

Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer

GCO# 06-0832
Investigator Initiated Phase I/II trial of combination intra-peritoneal Docetaxel and intravenous pegylated liposomal doxorubicin in persistent epithelial ovarian, peritoneal and fallopian tube carcinoma.

GCO # 04-0754
A Phase lll, Double-Blind, Randomized, Controlled, Multi-Center, Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals ' HPV-16/18 VLP/AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age
Protocol 580299/008

GCO # 07-0267
A Phase lllb, Observer-Blind, Randomized, Multicenter Study With Two Parallel Groups to Compare the Immunogenicity of GlaxoSmithKline Biological 's HPV-16/18 L 1/AS04 Vaccine Versus Merck 's Gardasil Vaccine When Administered Intramuscularly According to a 3-Dose Schedule in Healthy Adult Females 18-45 Years of Age
Protocol 108933 (HPV-010)

Translational Research

  • KLF6 is a novel regulator of VEGF in Ovarian cancer cell lines.
  • Utility of a novel microarray assessment of critical signaling pathways in ovarian cancer
  • MicroRNA signatures in Human Ovarian cancer and response to chemotherapy.
  • Comparative Genomic Hypridiztion (CGH) Predicts Time to Recurrence in Primary Ovarian Carcinoma.
  • Combination anti-estrogen and proteosome inhibitor biologic therapy for uterine cancer.


Nezhat F, Prasad Hayes M, Peiretti M, Rahaman J. Laparoscopic radical parametrectomy and partial vaginectomy for recurrent endometrial cancer. Gynecol Oncol 2007 Feb; 104(2): 494-496.

Rahaman J, Berkowitz R, Mitty H, Gaddipati S, Brown B, Nezhat F. Minimally Invasive Managemant of Advanced Abdominal Pregnancy. Obstet Gynecol 2004; 103(5): 1064-1068.

Nezhat F, Jyoti Y, Rahaman J, Gretz H, Cohen CJ. Analysis of survival after laparoscopic management of endometrial cancer. J Minim Invasive Gynecol 2008 Mar-Apr; 15(2): 181-187.

Zakashansky K, Chuang L, Gretz HF, Nagarsheth N, Rahaman J, Nezhat FN. A case controlled study of total laparoscopic radical hysterectomy with pelvic lymphadenectomy versus radical abdominal hysterectomy in a fellowship training program. Int J Gynecol Cancer 2007 Mar 26; [Epub ahead of print] .

Nezhat F, Jyoti Y, Rahaman J, Gretz H, Gardner G, Cohen CJ. Laparoscopic lymphadnectomy using the ultrasonically activated shears: Analysis of the first 100 Cases. Gynecol Oncol 2005 May; 97: 813-819.

Rahaman J, Dottino P, Jennings TS, Holland J, Cohen CJ. The Second-Look operation improves survival in sub-optimally debulked Stage III ovarian cancer patients. Int J Gynecol Cancer 2005; 15(1): 1-7.

Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman J, Robson ME, Offit K, Barakat RR, Soslow RA, Boyd J. Fallopian Tube and Primary Peritoneal Carcinoma Associated with BRCA Mutation. J Clin Oncol 2003; 21: 4222-4227.

Nezhat F, Cohen CJ, Rahaman J, Gretz H, Cole P, Kalir T. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts. Cancer 2002; 94(11): 2935-2940.

Jennings TS, Dottino P, Rahaman J, Cohen CJ. Results of selective use of operative laparoscopy in gynecologic oncology. Gynecol Oncol 1998; 70: 323-328.

Cohen CJ, Rahaman J. Endometrial Cancer: Management of high risk and recurrence including the Tamoxifen controversy. Cancer 1995; 76: 2044-2052.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Rahaman did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.

Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.

Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


1136 Fifth Avenue, Suite 1B
New York, NY 10128

Tel: 212-427-1415
Fax: 212-427-1420


Klingenstein Pavillion Floor 9th
1176 Fifth Avenue
New York, NY 10029

New Office

1136 Fifth Avenue, Suite 1B
New York, NY 10128

Tel: 212-427-1415
Fax: 212-427-1420
Get Directions